Pluristem Therapeutics Inc. (PSTI)’s Financial Results Comparing With ARCA biopharma Inc. (NASDAQ:ABIO)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) and ARCA biopharma Inc. (NASDAQ:ABIO) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pluristem Therapeutics Inc. N/A 1254.70 27.98M -0.25 0.00
ARCA biopharma Inc. N/A 0.00 7.93M -0.82 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Pluristem Therapeutics Inc. and ARCA biopharma Inc.


Table 2 demonstrates the return on assets, net margins and return on equity of Pluristem Therapeutics Inc. and ARCA biopharma Inc.

Net Margins Return on Equity Return on Assets
Pluristem Therapeutics Inc. 0.00% -113.7% -81.6%
ARCA biopharma Inc. 0.00% 0% 0%

Volatility & Risk

Pluristem Therapeutics Inc.’s volatility measures that it’s 34.00% more volatile than Standard & Poor’s 500 due to its 1.34 beta. Competitively, ARCA biopharma Inc.’s 108.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.08 beta.


Pluristem Therapeutics Inc. has a Current Ratio of 2.5 and a Quick Ratio of 2.5. Competitively, ARCA biopharma Inc.’s Current Ratio is 8.5 and has 8.5 Quick Ratio. ARCA biopharma Inc.’s better ability to pay short and long-term obligations than Pluristem Therapeutics Inc.

Institutional & Insider Ownership

Pluristem Therapeutics Inc. and ARCA biopharma Inc. has shares held by institutional investors as follows: 5.4% and 15.4%. Pluristem Therapeutics Inc.’s share held by insiders are 10.7%. Comparatively, ARCA biopharma Inc. has 0.89% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Pluristem Therapeutics Inc. -6.85% -16.57% -11.17% -28.4% -32.67% 21.74%
ARCA biopharma Inc. 5.75% 9.55% -15.6% -24.74% -36.11% 37.93%

For the past year Pluristem Therapeutics Inc. has weaker performance than ARCA biopharma Inc.


ARCA biopharma Inc. beats Pluristem Therapeutics Inc. on 5 of the 7 factors.

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.